ClinicalTrials.gg
WithdrawnNCT04151563CheckMate 79XUpdated Dec 19, 2023

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

A Phase 1/2 interventional study of nivolumab and ipilimumab in Carcinoma, Non-small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Withdrawn at 23 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-19.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Business objectives have changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Carcinoma with a site in Argentina — 4 open to participants now, 12 under way, 11 of them phase 3. Carcinoma · Argentina.

Enrollment
24th of 24
0 · median 709
Started
2021
with 1 other
Phase 1/2
Only one
of the 25
Registered
17th of 25
by date
Lead sponsor
1 of 25
Bristol-Myers Squibb

Among the 25 studies in Carcinoma with a site in Argentina, this one is the 24th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2021, is the only one in phase 1/2, and was the 17th registered.

Carcinoma

736 studies on the registry are indexed under Carcinoma; 149 are open to participants now.

Browse Carcinoma studies →

Open to participants now

4 of the 25 studies in Carcinoma with a site in Argentina are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 115 Carcinoma studies recruiting now, 92 (80%) set no upper age limit and 14 (12%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Carcinoma with a site in Argentina, or all of them as a file.
02

Study summary

This study is for participants with Non-small Cell Lung Cancer that has spread or has reoccurred after failure of Chemotherapy and Immunotherapy

03

Conditions studied

  • Carcinoma, Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com.

Inclusion criteria

Inclusion Criteria

  • or cytologically-documented Stage IV A/B non-small cell lung Cancer, stage IIIB/C disease failed concurrent chemoRT.
  • Performance Status of ≤ 1.
  • Radiologically-documented disease progression on one /anti-PD-L1 therapy and one platinum-based doublet regimen given either concurrently or sequentially within 90 days after the last dose of anti-PD-(L)1.
  • All participants must have tumor tissue submitted prior to randomization, either a recent obtained on/after the date of disease progression of the last prior anticancer therapy and within 3 months prior to enrollment, or a fresh biopsy obtained during the screening period.
  • Prior toxicities must have resolved to grade ≤1.
  • Women of (WOCBP) must have a negative serum or urine pregnancy test and must not be breastfeeding.
  • Males who are sexually active with WOCBP must agree to follow instructions for method(s) of . In addition, male participants must be willing to refrain from sperm donation during this time and must agree to follow instructions for method(s) of contraception. Azoospermic males are exempt from contraceptive requirements as well as WOCBP who are continuously not heterosexually active, however, a pregnancy test will still be required.

Exclusion criteria

Exclusion Criteria

  • Prior treatment with Docetaxel.
  • Untreated , carcinomatous meningitis or .
  • Any tumor invading the Superior Vena Cava other blood vessel, GI Tract or Trachea.
  • EGFR mutations, ALK translocations, ROS1 translocations which are sensitive to inhibitor therapy.
  • History of cerebrovascular accident and coagulation disorders.
  • Participants with interstitial lung disease, history of cerebrovascular accident or history of abdominal fistula, gastrointestinal perforation, bowel obstruction, intra-abdominal abscess or grade 3-4 bleeding event within 6 months prior to randomization.
  • Known toxicity on prior treatment.
  • Participants who received more than one line of anti- PD-1/PD-L1 treatment.
  • Participants who received previous CTLA-4 inhibitor treatment.
  • Participants with known BRAF V600E mutation which are sensitive to available targeted inhibitor therapy are excluded.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Arm A: cabozantinib + nivolumab + ipilimumab

    Biological: nivolumab · Biological: ipilimumab · Drug: cabozantinib

  • Experimental
    Arm B: cabozantinib + nivolumab

    Biological: nivolumab · Drug: cabozantinib

  • Experimental
    Arm C: nivolumab + ramucirumab + docetaxel

    Biological: nivolumab · Biological: docetaxel · Biological: ramucirumab

  • Experimental
    Arm D: lucitanib + nivolumab

    Biological: nivolumab · Drug: lucitanib

  • Experimental
    Arm E: nivolumab + docetaxel

    Biological: nivolumab · Biological: docetaxel

  • Active comparator
    Arm F: docetaxel

    Biological: docetaxel

Interventions

  • Biologicalnivolumab

    Specified dose on Specified days

    Also known as: OPDIVO, BMS-936558

  • Biologicalipilimumab

    Specified dose on Specified days

    Also known as: YERVOY

  • Specified dose on Specified days

    Also known as: CABOMETYX

  • Biologicaldocetaxel

    Specified dose on Specified days

  • Biologicalramucirumab

    Specified dose on Specified days

    Also known as: CYRAMZA

  • Specified dose on Specified days

    Also known as: CO-3810

06

What researchers measure

Primary outcomes

  1. Overall Reponse Rate (ORR) using RECIST 1.1 per Blinded Independent Central Review (BICR) assessment

    Time frame: approximately 33 months

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Up to 5 Years

  2. Duration of Response (DOR) by BICR using RECIST 1.1

    Time frame: approximately 33 months

  3. Progression-Free Survival (PFS) by BICR using RECIST 1.1

    Time frame: Up to 5 Years

  4. Incidence of Adverse Events (AEs)

    Time frame: Up to 5 Years

  5. Incidence of Serious Adverse Events (SAEs)

    Time frame: Up to 5 Years

  6. Incidence of Select AEs

    Time frame: Up to 5 Years

07

Study locations

23 sites
  • Local Institution
    Detroit, Michigan 48201, United States
  • Local Institution
    Ciudad Autónoma De Buenos Aires, Buenos Aires 1426, Argentina
  • Local Institution
    Buenos Aires, Distrito Federal 1431, Argentina
  • Local Institution
    Buenos Aires, Distrito Federal C1199ABB, Argentina
  • Local Institution
    Caba, Distrito Federal 1430, Argentina
  • Local Institution
    Capital, Distrito Federal C1280, Argentina
  • Local Institution
    Charleroi, 6000, Belgium
  • Local Institution
    Gilly, 6060, Belgium
  • Local Institution
    Leuven, 3000, Belgium
  • Local Institution
    Copenhagen Ø, 2100, Denmark
  • Local Institution
    Athens, 11527, Greece
  • Local Institution
    Neo Faliro, 18547, Greece
  • Local Institution
    Torreon, Coahuila 27010, Mexico
  • Local Institution
    Ciudad de México, Distrito Federal 03240, Mexico
  • Local Institution
    Zapopan, Jalisco 44280, Mexico
  • Local Institution
    Heroica Puebla de Zaragoza, Puebla 72530, Mexico
  • Local Institution
    Amsterdam, 1066 CX, Netherlands
  • Local Institution
    Rotterdam, 3015 GD, Netherlands
  • Local Institution
    Oslo, 0379, Norway
  • Local Institution
    Warszawa, Mazowieckie 02-781, Poland
  • Local Institution
    Krakow, 30-688, Poland
  • Local Institution
    Craiova, 200347, Romania
  • Local Institution
    Timisoara, 300696, Romania
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2021; primary completion for Dec 2023, 32 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2019
First posted
Nov 5, 2019
StartEst.
Apr 15, 2021
Primary completionEst.
Dec 17, 2023
CompletionEst.
May 13, 2026
Last update
Dec 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04151563
Collaborators
Clovis Oncology, Inc., Exelixis, Eli Lilly and Company
Responsible party
Sponsor
First posted
Nov 5, 2019
Start date
Apr 15, 2021 (estimated)
Primary completion
Dec 17, 2023 (estimated)
Completion
May 13, 2026 (estimated)
Last update
Dec 19, 2023

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab · Cabozantinib · Docetaxel

Start the discussion